X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Orchid Chemicals - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs ORCHID PHARMA LTD - Comparison Results

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA ORCHID PHARMA LTD ALEMBIC PHARMA/
ORCHID PHARMA LTD
 
P/E (TTM) x 28.7 -0.5 - View Chart
P/BV x 6.6 0.4 1,820.8% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 ALEMBIC PHARMA   ORCHID PHARMA LTD
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
ORCHID PHARMA LTD
Sep-13
ALEMBIC PHARMA/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs792194 408.1%   
Low Rs44335 1,265.7%   
Sales per share (Unadj.) Rs167.0276.5 60.4%  
Earnings per share (Unadj.) Rs38.2-79.2 -48.2%  
Cash flow per share (Unadj.) Rs42.0-43.5 -96.6%  
Dividends per share (Unadj.) Rs4.000-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs84.953.9 157.4%  
Shares outstanding (eoy) m188.5270.45 267.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.70.4 892.5%   
Avg P/E ratio x16.2-1.4 -1,119.1%  
P/CF ratio (eoy) x14.7-2.6 -557.9%  
Price / Book Value ratio x7.32.1 342.5%  
Dividend payout %10.50-   
Avg Mkt Cap Rs m116,3838,067 1,442.8%   
No. of employees `000NA2.8 0.0%   
Total wages/salary Rs m4,2142,527 166.8%   
Avg. sales/employee Rs ThNM6,956.1-  
Avg. wages/employee Rs ThNM902.5-  
Avg. net profit/employee Rs ThNM-1,993.0-  
INCOME DATA
Net Sales Rs m31,48719,477 161.7%  
Other income Rs m55407 13.5%   
Total revenues Rs m31,54219,884 158.6%   
Gross profit Rs m10,0601,103 912.4%  
Depreciation Rs m7222,519 28.7%   
Interest Rs m375,227 0.7%   
Profit before tax Rs m9,356-6,236 -150.0%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m0511 0.0%   
Tax Rs m2,160-125 -1,725.4%   
Profit after tax Rs m7,194-5,580 -128.9%  
Gross profit margin %31.95.7 564.4%  
Effective tax rate %23.12.0 1,150.1%   
Net profit margin %22.8-28.7 -79.7%  
BALANCE SHEET DATA
Current assets Rs m15,06611,014 136.8%   
Current liabilities Rs m7,67432,060 23.9%   
Net working cap to sales %23.5-108.1 -21.7%  
Current ratio x2.00.3 571.4%  
Inventory Days Days6795 70.6%  
Debtors Days Days4134 121.1%  
Net fixed assets Rs m8,23729,440 28.0%   
Share capital Rs m377705 53.5%   
"Free" reserves Rs m15,4162,043 754.7%   
Net worth Rs m16,0053,800 421.2%   
Long term debt Rs m09,018 0.0%   
Total assets Rs m24,59446,510 52.9%  
Interest coverage x255.2-0.2 -132,166.0%   
Debt to equity ratio x02.4 0.0%  
Sales to assets ratio x1.30.4 305.7%   
Return on assets %29.4-0.8 -3,868.5%  
Return on equity %44.9-146.9 -30.6%  
Return on capital %58.7-3.7 -1,571.1%  
Exports to sales %55.737.9 147.2%   
Imports to sales %10.422.6 46.1%   
Exports (fob) Rs m17,5517,378 237.9%   
Imports (cif) Rs m3,2834,406 74.5%   
Fx inflow Rs m17,8117,513 237.1%   
Fx outflow Rs m5,3185,649 94.1%   
Net fx Rs m12,4931,865 670.0%   
CASH FLOW
From Operations Rs m9,3041,682 553.2%  
From Investments Rs m-3,105-9,860 31.5%  
From Financial Activity Rs m-1,9596,644 -29.5%  
Net Cashflow Rs m4,240-1,535 -276.2%  

Share Holding

Indian Promoters % 74.1 32.3 229.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 4.6 63.0%  
FIIs % 9.1 3.3 275.8%  
ADR/GDR % 0.0 4.6 -  
Free float % 13.9 55.3 25.1%  
Shareholders   49,328 84,811 58.2%  
Pledged promoter(s) holding % 0.0 54.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   ELDER PHARMA  FDC LTD.  SUN PHARMA  STRIDES SHASUN LTD  TTK HEALTHCARE  

Compare ALEMBIC PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Of Mr Modi Providing Impetus to Defense Industry and Key Stocks in Action Today(Pre-Open)

Addressing the Uttar Pradesh Investors Summit, Mr. Modi announced the creation of a defense industrial corridor in Bundelkhand.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Feb 21, 2018 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 5-YR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS